Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - eFFECTOR Therapeutics, Inc. | d475503dex322.htm |
| EX-31.2 - EX-31.2 - eFFECTOR Therapeutics, Inc. | d475503dex312.htm |
| EX-31.1 - EX-31.1 - eFFECTOR Therapeutics, Inc. | d475503dex311.htm |
| 10-Q - FORM 10-Q - eFFECTOR Therapeutics, Inc. | d475503d10q.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Locust Walk Acquisition Corp. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission (the “Report”), I, Chris Ehrlich, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: June 3, 2021
| /s/ Chris Ehrlich |
| Chris Ehrlich |
| Chief Executive Officer |
| (Principal Executive Officer) |